With global military spending rising and not expected to change soon, it’s a strong and lasting thematic driver. Here are two Australian stocks that can be expected to benefit.
Here are two listed property exposures I think look very attractive at current prices.
The ASX banks are all trading well above fair value, and there are no investment prospects in the sector right now. If that’s what you’re thinking, take another look: here are two well-run Australian banks that are nicely poised to deliver returns to investors.
Here are three uranium plays that all look capable of moving higher from current levels.
Looking for value on the ASX? So is everybody. Here are two good-value stocks, operating in global markets that they understand very well.
The human healthcare industry can be a frustrating place to invest but here are three examples on the ASX that are making a good fist of establishing their respective devices in world markets.
A small cohort of stocks brought out very good results, but I maintain they still have some scope for share price rises. Here are three standout situations.
On valuation grounds, my view is that our Big Four banks are all candidates for a ‘sell’ rating. But they’re not the only popular stocks where analysts are warning of clear over-valuation and potential for share-price degradation.
Here are two software-as-a-service (SaaS) companies I think are good prospects of building profitable global businesses, as they embrace the SaaS revolution and move away from their legacy enterprise software businesses
One of the most exciting areas in medicine is the emerging field of CAR-T cell therapy, a potentially revolutionary treatment in cancer and a range of other serious diseases. As a world-class centre of medical research, Australia is at the forefront of this area. Here are four ASX-listed companies involved in this fascinating area.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.